{"id":2044,"date":"2020-04-12T09:10:23","date_gmt":"2020-04-12T09:10:23","guid":{"rendered":"https:\/\/icrowdnewswire.com\/2020\/04\/08\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-southern\/"},"modified":"2020-04-12T09:10:23","modified_gmt":"2020-04-12T09:10:23","slug":"anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south","status":"publish","type":"post","link":"https:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/","title":{"rendered":"ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc."},"content":{"rendered":"<p><span class=\"xn-location\">NEW YORK<\/span>&nbsp;and&nbsp;<span class=\"xn-location\">SAN DIEGO<\/span>,&nbsp;&nbsp;&#8212;&nbsp;<span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span>&nbsp;&amp; Herz LLP&nbsp;&nbsp;announces that a class action lawsuit has been filed in&nbsp;<span class=\"xn-location\">United States<\/span>&nbsp;District Court for Southern District&nbsp;of California&nbsp;on behalf of investors who purchased AnaptysBio, Inc. (&#8220;AnaptysBio&#8221; or the Company&#8221;) (NASDAQ:&nbsp;ANAB) securities between&nbsp;<span class=\"xn-chron\">October 10, 2017<\/span>&nbsp;and&nbsp;<span class=\"xn-chron\">November 7, 2019<\/span>, inclusive (the &#8220;Class Period&#8221;).<\/p>\n<p><strong>All &nbsp;investors who purchased shares&nbsp;<\/strong><strong>of<\/strong>&nbsp;<strong>AnaptysBio, Inc.<\/strong><strong>&nbsp;and incurred losses are urged<\/strong><strong>&nbsp;to contact the firm immediately at&nbsp;classmember@whafh.com&nbsp;or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action or&nbsp;join the case&nbsp;on our website,&nbsp;www.whafh.com.<\/strong><\/p>\n<p>If you have incurred losses in the shares&nbsp;of AnaptysBio, Inc.<strong>,&nbsp;<\/strong><strong>yo<\/strong><strong>u may,<\/strong>&nbsp;<strong>no later than&nbsp;<span class=\"xn-chron\">May 26, 2020<\/span><\/strong><strong>,&nbsp;<\/strong>request that the Court appoint you lead plaintiff of the proposed class.<\/p>\n<p class=\"prntac\">## Follow the firm and learn about newly filed cases on&nbsp;Twitter&nbsp;and&nbsp;Facebook&nbsp;##<\/p>\n<p class=\"prntac\"><strong>CLICK HERE TO JOIN THE CASE&nbsp;<\/strong><\/p>\n<p>On&nbsp;<span class=\"xn-chron\">March 26, 2018<\/span>, AnaptysBio revealed data from an interim analysis of a Phase 2a trial for etokimab in adult patients with peanut allergies. Though the Company reported improvement among patients who received a single dose of etokimab compared to patients dosed with a placebo, later that day, an analyst from RBC Capital Markets issued a report that questioned the accuracy of that data.<\/p>\n<p>On this news, the Company&#8217;s share price fell&nbsp;<span class=\"xn-money\">$6.31<\/span>&nbsp;per share, or over 5%, to close at&nbsp;<span class=\"xn-money\">$107.52<\/span>&nbsp;per share on&nbsp;<span class=\"xn-chron\">March 27, 2018<\/span>.<\/p>\n<p>Then on&nbsp;<span class=\"xn-chron\">June 21, 2019<\/span>, an analyst from Credit Suisse issued a report questioning the accuracy of the Company&#8217;s Phase 2a atopic dermatitis data, concluding that due to lack of critical details provided by the Company as well as the study&#8217;s small sample size,&nbsp;<em>&#8220;we must consider the possibility that the presence of rescue medications could have influenced the trial&#8217;s response rates&#8221;<\/em>&nbsp;and&nbsp;<em>&#8220;we are now less certain about etokimab&#8217;s efficacy profile.&#8221;&nbsp;<\/em>Thus, Credit Suisse downgraded AnaptysBio stock to neutral from outperform and slashed its price target to&nbsp;<span class=\"xn-money\">$79<\/span>&nbsp;from&nbsp;<span class=\"xn-money\">$137<\/span>.<\/p>\n<p>On this news, the Company&#8217;s share price fell&nbsp;<span class=\"xn-money\">$7.78<\/span>&nbsp;per share, or over 11%, to close at&nbsp;<span class=\"xn-money\">$59.24<\/span>&nbsp;per share on&nbsp;<span class=\"xn-chron\">June 21, 2019<\/span>.<\/p>\n<p>Finally, on&nbsp;<span class=\"xn-chron\">November 8, 2019<\/span>, the Company announced&nbsp;<em>&#8220;very disappoint[ing]&#8221;&nbsp;<\/em>data from its ATLAS trial, a Phase&nbsp;<span class=\"xn-money\">2b<\/span>&nbsp;multi-dose study which evaluated the efficacy of etokimab in patients with moderate-to-severe atopic dermatitis. Specifically, AnaptysBio disclosed that each of the etokimab dosing arms&nbsp;<em>&#8220;failed to meet the primary endpoint of the trial&#8221;<\/em>&nbsp;and revealed that, as a result of this data, it had postponed the initiation of its Phase&nbsp;<span class=\"xn-money\">2b<\/span>&nbsp;etokimab clinical trial in asthma.<\/p>\n<p>On this news, the Company&#8217;s share price fell&nbsp;<span class=\"xn-money\">$25.98<\/span>&nbsp;per share, or over 71%, to<br class=\"dnr\" \/>close at&nbsp;<span class=\"xn-money\">$10.18<\/span>&nbsp;per share on&nbsp;<span class=\"xn-chron\">November 8, 2019<\/span>.<\/p>\n<p><span class=\"xn-person\">Wolf Haldenstein<\/span>&nbsp;has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.&nbsp; The firm has attorneys in various practice areas; and offices in&nbsp;<span class=\"xn-location\">New York<\/span>,&nbsp;<span class=\"xn-location\">Chicago<\/span>&nbsp;and San Diego.&nbsp; The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.<\/p>\n<p>If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact&nbsp;<span class=\"xn-person\">Wolf Haldenstein<\/span>&nbsp;by telephone at (800) 575-0735, via e-mail at&nbsp;classmember@whafh.com, or visit our website at&nbsp;&nbsp;www.whafh.com.<\/p>\n<p>Contact:<\/p>\n<p><span class=\"xn-person\">Wolf Haldenstein Adler Freeman<\/span>&nbsp;&amp; Herz LLP<br class=\"dnr\" \/><span class=\"xn-person\">Kevin Cooper, Esq.<\/span><br class=\"dnr\" \/><span class=\"xn-person\">Gregory Stone<\/span>, Director of Case and Financial Analysis<br class=\"dnr\" \/>Email:&nbsp;gstone@whafh.com,&nbsp;kcooper@whafh.com&nbsp;or&nbsp;classmember@whafh.com<br class=\"dnr\" \/>Tel: (800) 575-0735 or (212) 545-4774<\/p>\n<p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.&nbsp;<\/p>\n<p class=\"tags\">\n<div><strong>See Campaign: <\/strong><a href=\"http:\/\/www.whafh.com\" target=\"_blank\">http:\/\/www.whafh.com<\/a><br \/><b>Contact Information:<\/b><br \/>Wolf Haldenstein Adler Freeman &#038; Herz LLP<br \/>\nKevin Cooper, Esq.<br \/>\nGregory Stone, Director of Case and Financial Analysis<br \/>\nEmail: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com<br \/>\nTel: (800) 575-0735 or (212) 545-4774<\/p>\n<p><b>Tags:<\/b><br \/><a href=\"\"><\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/wire\/\" rel=\"category tag\">Wire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/news-category\/legal-newswire\/\" rel=\"category tag\">Legal Newswire<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/global-regions\/united-states\/\" rel=\"category tag\">United States<\/a>, <a href=\"https:\/\/icrowdnewswire.com\/category\/language\/english\/\" rel=\"category tag\">English<\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"\" alt=\"image\" width=\"400\" height=\"300\" class=\"cwdfimg\" \/><\/div>\n<div>\n<h3>Contact Information:<\/h3>\n<p>Wolf Haldenstein Adler Freeman &#038; Herz LLP<br \/>\nKevin Cooper, Esq.<br \/>\nGregory Stone, Director of Case and Financial Analysis<br \/>\nEmail: gstone@whafh.com, kcooper@whafh.com or classmember@whafh.com<br \/>\nTel: (800) 575-0735 or (212) 545-4774<\/p>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK&nbsp;and&nbsp;SAN DIEGO,&nbsp;&nbsp;&mdash;&nbsp;Wolf Haldenstein Adler Freeman&nbsp;&amp; Herz LLP&nbsp;&nbsp;announces that a class action lawsuit has been filed in&nbsp;United States&nbsp;District Court for Southern District&nbsp;of California&nbsp;on behalf of investors who purchased AnaptysBio, Inc. (&ldquo;AnaptysBio&rdquo; or the Company&rdquo;) (NASDAQ:&nbsp;ANAB) securities between&nbsp;October 10, 2017&nbsp;and&nbsp;November 7, 2019, inclusive (the &ldquo;Class Period&rdquo;). All &nbsp;investors who purchased shares&nbsp;of&nbsp;AnaptysBio, Inc.&nbsp;and incurred losses are urged&nbsp;to &hellip; <a href=\"https:\/\/icrowdnewswire.com\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-southern\/\">Continue reading <span>ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc.<\/span><\/a> <a href=\"https:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/\" class=\"more-link\">Continue Reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":49,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3,12,22,54],"tags":[],"class_list":["post-2044","post","type-post","status-publish","format-standard","hentry","category-english","category-legal-newswire","category-united-states","category-wire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc. - Business<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc. - Business\" \/>\n<meta property=\"og:description\" content=\"NEW YORK&nbsp;and&nbsp;SAN DIEGO,&nbsp;&nbsp;&mdash;&nbsp;Wolf Haldenstein Adler Freeman&nbsp;&amp; Herz LLP&nbsp;&nbsp;announces that a class action lawsuit has been filed in&nbsp;United States&nbsp;District Court for Southern District&nbsp;of California&nbsp;on behalf of investors who purchased AnaptysBio, Inc. (&ldquo;AnaptysBio&rdquo; or the Company&rdquo;) (NASDAQ:&nbsp;ANAB) securities between&nbsp;October 10, 2017&nbsp;and&nbsp;November 7, 2019, inclusive (the &ldquo;Class Period&rdquo;). All &nbsp;investors who purchased shares&nbsp;of&nbsp;AnaptysBio, Inc.&nbsp;and incurred losses are urged&nbsp;to &hellip; Continue reading ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc. Continue Reading &rarr;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/\" \/>\n<meta property=\"og:site_name\" content=\"Business\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-12T09:10:23+00:00\" \/>\n<meta name=\"author\" content=\"Charles Brown\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Charles Brown\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/\",\"url\":\"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/\",\"name\":\"ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc. - Business\",\"isPartOf\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#website\"},\"datePublished\":\"2020-04-12T09:10:23+00:00\",\"author\":{\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/2fd525425fcc6d62586cc2ba1afc789b\"},\"breadcrumb\":{\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ipsnews.net\/business\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ipsnews.net\/business\/#website\",\"url\":\"https:\/\/ipsnews.net\/business\/\",\"name\":\"Business\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ipsnews.net\/business\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/2fd525425fcc6d62586cc2ba1afc789b\",\"name\":\"Charles Brown\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/6ea0b826aeecf3e7e0df104a1c7ad5a9950e017f02e425f20d3d64a62c0db070?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/6ea0b826aeecf3e7e0df104a1c7ad5a9950e017f02e425f20d3d64a62c0db070?s=96&d=mm&r=g\",\"caption\":\"Charles Brown\"},\"sameAs\":[\"https:\/\/icrowdnewswire.com\/fc\"],\"url\":\"https:\/\/ipsnews.net\/business\/author\/charles-brown\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc. - Business","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/","og_locale":"en_US","og_type":"article","og_title":"ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc. - Business","og_description":"NEW YORK&nbsp;and&nbsp;SAN DIEGO,&nbsp;&nbsp;&mdash;&nbsp;Wolf Haldenstein Adler Freeman&nbsp;&amp; Herz LLP&nbsp;&nbsp;announces that a class action lawsuit has been filed in&nbsp;United States&nbsp;District Court for Southern District&nbsp;of California&nbsp;on behalf of investors who purchased AnaptysBio, Inc. (&ldquo;AnaptysBio&rdquo; or the Company&rdquo;) (NASDAQ:&nbsp;ANAB) securities between&nbsp;October 10, 2017&nbsp;and&nbsp;November 7, 2019, inclusive (the &ldquo;Class Period&rdquo;). All &nbsp;investors who purchased shares&nbsp;of&nbsp;AnaptysBio, Inc.&nbsp;and incurred losses are urged&nbsp;to &hellip; Continue reading ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc. Continue Reading &rarr;","og_url":"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/","og_site_name":"Business","article_published_time":"2020-04-12T09:10:23+00:00","author":"Charles Brown","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Charles Brown","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/","url":"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/","name":"ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc. - Business","isPartOf":{"@id":"https:\/\/ipsnews.net\/business\/#website"},"datePublished":"2020-04-12T09:10:23+00:00","author":{"@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/2fd525425fcc6d62586cc2ba1afc789b"},"breadcrumb":{"@id":"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/ipsnews.net\/business\/2020\/04\/12\/anaptysbio-inc-class-action-alert-wolf-haldenstein-adler-freeman-herz-llp-reminds-investors-that-a-securities-class-action-lawsuit-has-been-filed-in-the-united-states-district-court-for-south\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ipsnews.net\/business\/"},{"@type":"ListItem","position":2,"name":"ANAPTYSBIO, INC. CLASS ACTION Alert: Wolf Haldenstein Adler Freeman &amp; Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for Southern District of California against AnaptysBio, Inc."}]},{"@type":"WebSite","@id":"https:\/\/ipsnews.net\/business\/#website","url":"https:\/\/ipsnews.net\/business\/","name":"Business","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ipsnews.net\/business\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/2fd525425fcc6d62586cc2ba1afc789b","name":"Charles Brown","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ipsnews.net\/business\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/6ea0b826aeecf3e7e0df104a1c7ad5a9950e017f02e425f20d3d64a62c0db070?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/6ea0b826aeecf3e7e0df104a1c7ad5a9950e017f02e425f20d3d64a62c0db070?s=96&d=mm&r=g","caption":"Charles Brown"},"sameAs":["https:\/\/icrowdnewswire.com\/fc"],"url":"https:\/\/ipsnews.net\/business\/author\/charles-brown\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/2044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/users\/49"}],"replies":[{"embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/comments?post=2044"}],"version-history":[{"count":1,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/2044\/revisions"}],"predecessor-version":[{"id":2045,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/posts\/2044\/revisions\/2045"}],"wp:attachment":[{"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/media?parent=2044"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/categories?post=2044"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ipsnews.net\/business\/wp-json\/wp\/v2\/tags?post=2044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}